<DOC>
	<DOCNO>NCT02398513</DOCNO>
	<brief_summary>The primary objective study define pharmacokinetic Regorafenib administer orally single agent Chinese patient advance solid tumor . The second objective include evaluation safety , tolerability , efficacy Chinese patent treat Regorafenib</brief_summary>
	<brief_title>Regorafenib Phase I Study Mainland Chinese Patients</brief_title>
	<detailed_description />
	<criteria>Signed informed consent ( IC ) obtain study specific procedure . Patients must able understand willing sign write informed consent Patients histologically cytologically confirm , refractory , locally advanced metastatic solid tumor candidate standard therapy specific clinical indication Regorafenib approve elsewhere world consider appropriate treatment option . Male female Chinese patient live China mainland &gt; = 18 year Patients must measurable nonmeasurable disease accord RECIST , version 1.1 Eastern Cooperative Oncology Group performance status ( ECOGPS 0 1 ) Body mass index ( BMI ) 18 33 kg/m2 inclusive Adequate bone marrow , liver , renal function assess follow laboratory requirement conduct within 7 day prior dose : Platelet count &gt; = 100,000/cubic millimeter ( mm3 ) , hemoglobin ( Hb ) &gt; = 9 g/dl , leukocyte count &gt; 3,000/mm3 , absolute neutrophil count ( ANC ) &gt; =1,500/mm3 . Transfusion meet inclusion criterion allow . Total bilirubin &lt; = 1.5 x upper limit normal ( ULN ) . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; = 3.0 x ULN ( &lt; = 5 x ULN patient liver involvement cancer ) Alkaline phosphatase limit &lt; = 2.5 x ULN ( &lt; = 5 x ULN patient whose cancer involve liver and/or bone ) Lipase &lt; = 1.5 x ULN Serum creatinine &lt; = 1.5 time ULN estimate creatinine clearance ( CLcr ) &gt; = 30 mL/min accord CockroftGault formula International normalize ratio ( INR ) &lt; = 1.5 x ULN partial thromboplastin time ( PTT ) activate partial thromboplastin time ( aPTT ) &lt; = 1.5 x ULN . Patients treat anticoagulant , e.g . warfarin heparin , allow participate provide prior evidence underlie abnormality parameter exist . Close monitoring least weekly evaluation perform INR PTT stable base predose measurement define local standard care . Life expectancy least 3 month . Women childbearing potential must pregnancy test perform maximum 7 day start study treatment , negative result must document start study treatment . Prior treatment Regorafenib Patients unable swallow retain oral medication Any malignant disease treat &lt; 3 year prior study entry , except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Staging : Ta , Tis T1 ) Symptomatic metastatic brain meningeal tumor patient &lt; 6 month definitive therapy , evidence tumor growth image study within 4 week prior study entry dexamethasone clinically stable respect tumor time study entry . Major surgical procedure , significant traumatic injury within 28 day start study medication History organ allograft Nonhealing wound , ulcer , bone fracture Uncontrolled hypertension ( systolic blood pressure &gt; 150 millimeter mercury ( mmHg ) diastolic blood pressure &gt; 90 mmHg despite optimal medical management ) Persistent proteinuria &gt; 3.5 g/24 hour measure urine proteincreatinine ratio random urine sample ( &gt; =Grade 3 , NCICTCAE v 4.03 ) . History cardiac disease : congestive heart failure ( CHF ) &gt; =NYHA ( New York Heart Association ) Class II . Active coronary artery disease unstable angina ( angina symptom rest ) newonset angina ( within last 3 month ) myocardial infarction ( MI ) within past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>